Clinical Trial Search

Primary: Change From Baseline in Mean Liver Fat — -3.18; -3.41; -0.09 Abs. % Change from Baseline Liver Fat — p=0.0655

Primary: Treatment Success — 21; 28 Participants

Primary: Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 — 1 Participants

Primary: Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18 — -21.73; 95.55 μmol/L — p=0.0464

Primary: Number of Participants Reporting Contact Sexual Violence Via Physical Tactics — 23; 32; 46; 35 Participants

Primary: Change From Baseline in Lip Fullness Grading Scale — .82 score on a scale

Primary: Clinically-indicated Major Adverse Cardiac Events — 0 Participants

Primary: Change From Baseline Neo-angiogenesis (Microvessel Density) at 6 Weeks — 2.82; 1.77 score on a scale — p=<0.01

Primary: Effects of CAREN Virtual Reality System on Obstacle Course Navigation — 51.25; 33.75 seconds

Primary: All Cause and Cause-specific Death — 500; 60; 270; 32 Participants

Primary: Number of Participants Subjective Usability Reporting — 14; 41; 2 Participants

Primary: The Tinnitus Functional Index — 22.85; 32.51; 55.01; 55.26 score on a scale

Primary: Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD (Homologous Recombination Deficiency) Subgroups (Part 1 of Study) — 388; 174; 160…

Primary: Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 — -9.0; 6.0 meters — p=0.0043

Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109